Mycoplasma contamination of cell cultures is one of the biggest problems in life science research. Any contamination invalidates all research on the cells, but mycoplasma – a group of small bacteria – is notoriously hard to detect.
Almost one in five (18%) of all cell cultures are contaminated with mycoplasma according to estimates, costing companies hundreds of millions of pounds.
The mycoplasma testing market is huge. It’s estimated to have a $943.4 million value and a compound annual growth rate of 14%
Given the problems it can cause, life science companies are adopting a zero tolerance policy for mycoplasma. But the current detection tools for mycoplasma are not sufficiently sensitive to achieve that.
SwiftDx’s pioneering technology will allow rapid, simple and routine testing of cell lines, saving companies millions in research and development downtime, deep cleaning and wasted work.